Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, Blázquez A, Cid J, Lozano M, Magnano L, Giné E, Correa JG, Mozas P, Rodríguez-Lobato LG, Rivero A, Montoro-Lorite M, Ayora P, Navarro S, Alserawan L, González-Navarro EA, Castellà M, Sánchez-Castañón M, Cabezón R, Benítez-Ribas D, Setoaín X, Rodríguez S, Brillembourg H, Varea S, Olesti E, Guillén E, Sáez-Peñataro J, de Larrea CF, López-Guillermo A, Pascal M, Urbano-Ispizua Á, Juan M, Delgado J. Martínez-Cibrián N, et al. Among authors: delgado j. Br J Haematol. 2024 Feb;204(2):525-533. doi: 10.1111/bjh.19170. Epub 2023 Oct 31. Br J Haematol. 2024. PMID: 37905734
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
Villamor N, Conde L, Martínez-Trillos A, Cazorla M, Navarro A, Beà S, López C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Giné E, González-Díaz M, Hernández JM, Colado E, Payer AR, Rayon C, Navarro B, José Terol M, Bosch F, Quesada V, Puente XS, López-Otín C, Jares P, Pereira A, Campo E, López-Guillermo A. Villamor N, et al. Among authors: delgado j. Leukemia. 2013 Apr;27(5):1100-6. doi: 10.1038/leu.2012.357. Epub 2012 Dec 6. Leukemia. 2013. PMID: 23295735
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.
Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N. Martínez-Trillos A, et al. Among authors: delgado j. Blood. 2014 Jun 12;123(24):3790-6. doi: 10.1182/blood-2013-12-543306. Epub 2014 Apr 29. Blood. 2014. PMID: 24782504 Free article.
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J, Salaverria I, Baumann T, Martínez-Trillos A, Lee E, Jiménez L, Navarro A, Royo C, Santacruz R, López C, Payer AR, Colado E, González M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrió A, Costa D, Clot G, Giné E, López-Guillermo A, Campo E, Beà S. Delgado J, et al. Haematologica. 2014 Nov;99(11):e231-4. doi: 10.3324/haematol.2014.108365. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997154 Free PMC article. No abstract available.
Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.
Esteban D, Tovar N, Jiménez R, Santacruz R, Baumann T, Pastor MC, de la Riva A, Carrera E, Chaves S, Royo C, Navarro A, Rodríguez S, Ayuso C, Riu G, Creus N, Gómez B, Giné E, López-Guillermo A, Delgado J. Esteban D, et al. Among authors: delgado j. Blood Cancer J. 2015 Oct 2;5(10):e356. doi: 10.1038/bcj.2015.78. Blood Cancer J. 2015. PMID: 26430727 Free PMC article. No abstract available.
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Delgado J, Martínez A, Villamor N, Campo E, López-Guillermo A. Rovira J, et al. Among authors: delgado j. Clin Cancer Res. 2016 Jun 1;22(11):2755-64. doi: 10.1158/1078-0432.CCR-15-1525. Epub 2016 Jan 20. Clin Cancer Res. 2016. PMID: 26792260
2,029 results